BME Eyes APA Status to Support OTC Transparency Data Services

BME will launch new services covering OTC trade data to support compliance with MiFID 2.

bolsa-madrid-bolsas-y-mercados-espanoles-bme

BME Market Data will apply for authorization from the supervisory authorities to operate as an Approved Publication Arrangement (APA), a new denomination envisaged by MiFID 2 in the context of the new European post-trade transparency framework.

Details on the trades reported will be disseminated through BME's datafeeds.

The APA authorization manages the system through which investment firms are obliged to publish details of their over-the-counter transactions in equities, fixed income

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@waterstechnology.com or view our subscription options here: http://subscriptions.waterstechnology.com/subscribe

You are currently unable to copy this content. Please contact info@waterstechnology.com to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Waterstechnology? View our subscription options

CME: CFTC OKs clearing move to Google Cloud

The CFTC has given the Chicago-based exchange approval to run its clearing and settlement infrastructure on the Google Cloud Platform, while the exchange and vendor have extended their partnership to last until at least 2037.

Cutting through the hype surrounding the FDTA rulemaking process

A bill requiring US regulators and institutions to adopt a machine-readable data framework for reporting purposes applies to entity identifiers, but not security identifiers, in a crucial difference, writes Scott Preiss, SVP and global head of Cusip Global Services.

Most read articles loading...

You need to sign in to use this feature. If you don’t have a WatersTechnology account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here